HR+ cells have been proposed as the cell-of-origin for ER+ breast cancer51 and since ER+ breast cancers comprise the majority of breast cancers diagnosed, repurposing metformin has the potential to broaden prevention/treatment options. The gene discussed is ESR1; the disease is breast cancer.